Trials / Recruiting
RecruitingNCT05366816
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
ctDNA-Guided Sunitinib And Regorafenib Therapy for Gastrointestinal Stromal Tumor (GIST)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's response to standard of care treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | 37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle. |
| DRUG | Regorafenib | 120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle. |
Timeline
- Start date
- 2023-10-17
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
- First posted
- 2022-05-09
- Last updated
- 2025-09-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05366816. Inclusion in this directory is not an endorsement.